Why Moderna Stock Was So Healthy This Week

Investors piled into its s over the week, sending it to a more than 12% gain over the period, according to data compiled by S&P Global Market Intelligence

Positive news from the lab was a significant factor in this

In a phase 3 clinical trial the vaccine, developed using Moderna's signature mRNA-based apach, duced a more robust immune response than a standard flu jab currently available on the market

Image source: Getty Images

That surely came as a relief to Moderna investors, since the company's stock-rattling news was its withdrawal of a Food and Drug Administration application for a combination COVID-19/flu vaccine in May

At the time, the company pledged to submit a new application based on efficacy data from the stand-alone trial

Along with the findings for mRNA-1010, Moderna said that it would also resubmit its application for the combination vaccine

As for the flu shot alone, in the press release detailing the trial's results the company quoted CEO Stéphane Bancel as saying that they "are a significant milestone in our effort to reduce the burden of influenza in older adults. " Waiting for further development(s) Although this development is the good news Moderna holders have been waiting for quite some time to receive, I personally don't think it makes the company's stock a buy in and of itself, as I can't imagine a new flu vaccine will light the world on fire

Having said that, Moderna does have an admirably loaded slate of development grams, so if one or several show mise the s might become more enticing

Eric Volkman has no position in any of the stocks mentioned

The Motley Fool recommends Moderna

The Motley Fool has a disclosure policy.